In this Review:
Improved OS with autologous SCT vs. CRD in newly diagnosed MM
Lenalidomide/dexamethasone ±elotuzumab in relapsed/refractory MM
Bortezomib/dexamethasone ±elotuzumab in relapsed/refractory MM
Ibrutinib in previously treated Waldenström’s macroglobulinaemia
Carfilzomib vs. bortezomib (with dexamethasone) in relapsed MM
Preparative VDT + melphalan in MM
Impact of MRD on survival in MM with CR
Impact of FISH abnormalities on MGUS progression risk
Daratumumab + pomalidomide dexamethasone, with backbone regimens, in MM
Pomalidomide + low-dose dexamethasone in refractory/relapsed MM
KCRD induction quadruplet for newly diagnosed, transplant-eligible MM
Please login below to download this issue (PDF)